drugset / Trial / NCT03444649
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
NaSingle-groupOpen-labelTreatment
Summary
This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the anthracycline/cytarabine combination as first-line induction treatment in AML patients fit for intensive treatment
Timeline
- Start
- 2018-09
- Primary completion
- 2019-08
- Completion
- 2019-10
Outcome
Outcome not reported
Stopped: “IMP will not be further developed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Background | Cytarabine | Small molecule | — | — |
| Background | Daunorubicin | Small molecule | — | — |
| Background | Idarubicin | Small molecule | — | — |